Nov 2, 4:07 PM ET
Jazz Pharmaceuticals announced its third quarter 2026 financial results, highlighting record quarterly revenues of $1.2 billion and raising its full-year 2026 total revenue guidance to a range of $4.775 billion to $4.85 billion. The company reported a GAAP net loss of $483.4 million for the quarter, primarily driven by a $754 million acquired in-process research and development expense related to the Actio Biosciences acquisition. Shareholders saw solid commercial execution, including growth in key product sales like Xywav and the recent launch of Ziihera.
- Total revenues reached $1.24 billion in 3Q26, representing a 10% increase year-over-year.
- GAAP net loss was $483.4 million in 3Q26, impacted by a $754 million acquired IPR&D charge for the Actio acquisition.
- Full-year 2026 total revenue guidance was raised to $4.775 billion to $4.85 billion.
- Xywav net product sales grew 12% year-over-year to $483 million in 3Q26.
Read the filing on SEC.gov ↗
Oct 26, 4:03 PM ET
Jazz Pharmaceuticals estimates a pre-tax charge of approximately $755 million for acquired in-process research and development from its Actio Biosciences acquisition, which closed September 15, 2026, in its third quarter of 2026. The company says the non-deductible charge would reduce both GAAP and non-GAAP adjusted earnings per share by approximately $11.00, and the figures are preliminary and subject to closing procedures.
- Pre-tax acquired IPR&D expense of approximately $755 million expected in the quarter ended September 30, 2026
- The charge is not tax deductible and is estimated to reduce GAAP and non-GAAP adjusted EPS by approximately $11.00 each
- Actio Biosciences, Inc. acquisition was completed on September 15, 2026; quarterly results have not been finalized and may differ
Read the filing on SEC.gov ↗
Oct 9, 9:02 AM ET
Jazz Pharmaceuticals said its Executive Vice President and Chief Commercial Officer, Samantha Pearce, notified the company on October 6, 2026 that she intends to retire. She will leave when a successor is appointed or by June 30, 2027, whichever comes first. The company plans a formal search that will consider internal and external candidates, so the change in a key commercial leadership role will take effect over time.
- Samantha Pearce notified Jazz of her intent to retire on October 6, 2026.
- Retirement takes effect on the earlier of her successor's appointment or June 30, 2027.
- Jazz plans a formal search that will consider both internal and external candidates.
Read the filing on SEC.gov ↗
Sep 23, 4:15 PM ET
Jazz Pharmaceuticals' subsidiary Jazz Financing Lux entered into Amendment No. 4 to its credit agreement on September 23, 2026, extending the maturity of the $1.9 billion Tranche B-2 dollar term loan from May 5, 2028 to May 5, 2033 and lowering its interest margin. The filing does not include new earnings, guidance, or changes to operations, so the effect on shareholders depends on the lower borrowing cost and longer repayment schedule.
- Maturity extended from May 5, 2028 to May 5, 2033 for the Tranche B-3 dollar term loans
- Applicable margin cut 50 basis points to 1.75% for Term SOFR borrowings and 0.75% for prime rate borrowings, with a 0.50% Term SOFR floor
- Principal outstanding of $1,895,000,000 before and after the amendment; Jazz Lux also borrowed $273,310,355.18 in additional term loans to repay non-converted loans
- Quarterly amortization of 0.25% of initial principal, with the remaining balance due May 5, 2033
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.